<?xml version='1.0' encoding='utf-8'?>
<CERIF xmlns='urn:xmlns:org:eurocris:cerif-1.5-1' xsi:schemaLocation='urn:xmlns:org:eurocris:cerif-1.5-1 http://www.eurocris.org/Uploads/Web%20pages/CERIF-1.5/CERIF_1.5_1.xsd' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' release='1.5' date='2012-10-07' sourceDatabase='Output Profile'>
<cfResPubl>
<cfResPublId>ibn-ResPubl-10491</cfResPublId>
<cfResPublDate>2006-10-02</cfResPublDate>
<cfVol>20</cfVol>
<cfIssue>5</cfIssue>
<cfStartPage>41</cfStartPage>
<cfISSN>1810-1852</cfISSN>
<cfURI>https://ibn.idsi.md/ro/vizualizare_articol/10491</cfURI>
<cfTitle cfLangCode='RO' cfTrans='o'>Utilizarea acidului alfa-lipoic (thiogamma 600) în tratamentul complex al piciorului diabetic</cfTitle>
<cfAbstr cfLangCode='RO' cfTrans='o'>S-a efectuat un studiu randomizat al eficacităţii tratamentului polineuropatiei diabetice în picior diabetic cu acid alfa-lipoic (Thiogamma 600®). În grupul de control (n=20) scorul NISll s-a micşorat cu 1,3 ± 0,3 iar ]n cel de studiu (n=20) cu 3,8 ± 0,7 (p<0,01), fapt ce dovedeşte eficienţa administrării Thiogamma 600® la pacienţii cu picior diabetic.</cfAbstr>
<cfAbstr cfLangCode='EN' cfTrans='o'>A randomized study of diabetic polineuropathy treatment efficacy of alpha lipoic acid (Thiogamma 600®) In the diabetic foot was carried out. The NISll score decreased in the control group with 1,3 ± 0,3 and In the study group with 3,8 ± 0,7 (p<0,01 ), that demonstrates the efficiency of the Thiogamma 600® administration in the patients with diabetic foot.</cfAbstr>
<cfResPubl_Class>
<cfClassId>eda2d9e9-34c5-11e1-b86c-0800200c9a66</cfClassId>
<cfClassSchemeId>759af938-34ae-11e1-b86c-0800200c9a66</cfClassSchemeId>
<cfStartDate>2006-10-02T24:00:00</cfStartDate>
</cfResPubl_Class>
<cfResPubl_Class>
<cfClassId>e601872f-4b7e-4d88-929f-7df027b226c9</cfClassId>
<cfClassSchemeId>40e90e2f-446d-460a-98e5-5dce57550c48</cfClassSchemeId>
<cfStartDate>2006-10-02T24:00:00</cfStartDate>
</cfResPubl_Class>
<cfPers_ResPubl>
<cfPersId>ibn-person-10675</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2006-10-02T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-35593</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2006-10-02T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-10999</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2006-10-02T24:00:00</cfStartDate>
</cfPers_ResPubl>
</cfResPubl>
<cfPers>
<cfPersId>ibn-Pers-10675</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-10675-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2006-10-02T24:00:00</cfStartDate>
<cfFamilyNames>Bernaz</cfFamilyNames>
<cfFirstNames>Eduard</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-35593</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-35593-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2006-10-02T24:00:00</cfStartDate>
<cfFamilyNames>Trestian</cfFamilyNames>
<cfFirstNames>Vitalii</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-10999</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-10999-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2006-10-02T24:00:00</cfStartDate>
<cfFamilyNames>Conţu</cfFamilyNames>
<cfFirstNames>Oleg</cfFirstNames>
</cfPersName_Pers>
</cfPers>
</CERIF>